The recent Cochrane review questioned whether amyloid-targeting monoclonal antibodies deliver meaningful benefits for people with early Alzheimer’s, and it also raised safety questions about brain swelling and bleeding. Experts and drugmakers have pushed back, saying the review’s methods lump different drugs together and overlook real-world patient experiences and longer-term data. The debate highlights a wider problem: removing amyloid from the brain is not automatically the same as helping patients live better, and researchers are calling for fresh approaches and more nuanced trials.
The review pooled results from 17 trials and more than 20,000 participants with mild cognitive impairment or early dementia and concluded that lowering amyloid produced little to no noticeable improvement in memory or everyday function. Researchers pointed out that while some trials showed statistically significant changes, those shifts did not translate into what clinicians would call a meaningful difference for patients. That distinction between statistical signals and real-life impact sits at the center of the controversy.
“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” said lead author Francesco Nonino, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy, in the release. “There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect,” he went on. “While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance. It is common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients.”
The review also flagged safety concerns, notably a higher incidence of brain swelling and bleeding detectable on scans in patients treated with anti-amyloid therapies. Many of those imaging changes were asymptomatic, but inconsistent symptom reporting across studies leaves long-term risks unclear. That uncertainty makes it hard to weigh potential benefits against possible harms for individual patients and families.
Authors urged researchers to explore additional biological pathways linked to Alzheimer’s beyond amyloid accumulation, arguing that removing plaques alone appears insufficient to halt cognitive decline. “Given the absence of correlation between amyloid removal and clinical benefit, we need to explore other pathways to help address this devastating disease.” That call reflects a growing sense that the field must broaden its targets and refine how success is measured.
Not everyone agrees with the Cochrane team. The Alzheimer’s Association argued the review overlooked patient perspectives and real-world outcomes, saying many people on these therapies experience better quality of life and more time with loved ones. “Many people living with mild cognitive impairment and mild dementia due to Alzheimer’s disease who are using these treatments are taking trips they weren’t sure they’d take, spending joyful time with friends and family, making plans for next month, doing things they love, and staying present in their lives and the lives of the people they care about,” the group said in a statement provided to Fox News Digital.
Drugmakers pushed back on methodological grounds, arguing that mixing data from failed and approved molecules masks benefits seen with individual therapies. “It pools data from across multiple amyloid-targeting therapies as a class, including molecules that did not achieve their clinical trial endpoints and were never granted regulatory approval,” a Lilly spokesperson told Fox News Digital. “Combining data on unsuccessful molecules with approved medicines artificially dilutes the observed benefit and produces class-level conclusions that do not reflect the evidence for any individual approved therapy.”
An Eisai spokesperson made a similar point about their drug, noting regulatory reviews and longer-term experience. “The U.S. Food and Drug Administration has stated that lecanemab is part of a newer generation of anti-amyloid therapies targeting aggregated amyloid and has learned from previous failures,” an Eisai spokesperson told Fox News Digital. “Extensive long-term clinical data out to four years and real-world experience with tens of thousands of patients globally show that patients who receive lecanemab continue to benefit from treatment.”
The review team acknowledged limits in the evidence, including short follow-up in some trials, differences in dosing and endpoints, and the focus on early-stage disease that may not apply to everyone. Senior author Edo Richard stressed the ongoing need for better options in clinic. “I see Alzheimer’s patients in my clinic every week and I wish I had an effective treatment to offer them,” said senior author Edo Richard, professor of neurology at Radboud University Medical Centre, in the release. “Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments.”
This is a messy moment for Alzheimer’s research: clear signals on plaque reduction, mixed signals on clinical benefit, and an active debate over how to interpret complex data. The takeaway for clinicians and families is to weigh trial data, real-world experience, and individual goals when considering treatment and to support efforts that investigate new biological targets and better outcome measures.
